Hermetica Superfood Encyclopedia
The Short Answer
Schizochytrium sp. microalgae synthesizes long-chain n-3 polyunsaturated fatty acids—primarily DHA (C22:6 n-3, comprising 40–50% of total fatty acids) and EPA (C20:5 n-3, typically under 10%)—via a polyketide synthase-like (PKS) enzyme complex, which incorporates these fatty acids into cell membranes, modulates eicosanoid signaling, and supports resolution of inflammation through resolvin and protectin biosynthesis. In cattle supplementation studies, Schizochytrium-derived omega-3 increased beef EPA content 4–6-fold and DHA content 8.5–11.4-fold relative to controls (p<0.001), demonstrating potent biofortification capacity, while human cardiovascular and anti-inflammatory benefits are extrapolated from the well-established EPA/DHA omega-3 literature rather than Schizochytrium-specific human trials.
CategoryExtract
GroupMarine-Derived
Evidence LevelPreliminary
Primary Keywordalgal omega-3 EPA DHA benefits
Algal Omega-3 (EPA/DHA) — botanical close-up
Health Benefits
**Cardiovascular Risk Reduction**
EPA and DHA reduce serum triglycerides, decrease platelet aggregation, and improve endothelial function via inhibition of thromboxane A2 synthesis and upregulation of nitric oxide production, outcomes well-documented for algal-derived omega-3 oils equivalent to fish oil sources.
**Anti-Inflammatory Activity**
EPA serves as a precursor to E-series resolvins and DHA to D-series resolvins and protectins, specialized pro-resolving mediators (SPMs) that actively terminate acute inflammation and reduce chronic low-grade inflammatory signaling without immunosuppression.
**Vegan Alternative to Fish Oil**: Schizochytrium sp
oil provides a direct, bioavailable source of preformed EPA and DHA for individuals avoiding animal products, circumventing the inefficient (<5–10%) endogenous conversion of ALA to EPA/DHA via delta-6 desaturase and elongase enzymes.
**Neurological and Cognitive Support**
DHA constitutes approximately 30–40% of fatty acids in the neuronal plasma membrane and synaptic vesicle membranes; adequate DHA status supports synaptic plasticity, neuroprotectin D1 synthesis, and is associated with reduced risk of cognitive decline in observational studies.
**Antioxidant Capacity Enhancement**
Animal studies using Schizochytrium supplementation demonstrated increased meat antioxidant capacity alongside elevated n-3 PUFA content; carotenoids and squalene co-produced by Schizochytrium contribute ancillary antioxidant activity in the oil matrix.
**Improved n-6
n-3 Ratio**: Dietary intake of Schizochytrium-derived EPA/DHA significantly lowers the n-6:n-3 PUFA ratio (p<0.001 in bovine models), which is associated in epidemiological literature with reduced systemic inflammation, improved insulin sensitivity, and lower cardiovascular event risk.
**Immune Modulation**
DHA and EPA alter lipid raft composition and toll-like receptor 4 (TLR4) signaling in immune cells, reducing NF-κB activation and downstream pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β), supporting immune homeostasis.
Origin & History
Natural habitat
Schizochytrium sp. is a heterotrophic marine thraustochytrid microalgae native to mangrove ecosystems and coastal marine sediments across tropical and subtropical regions, including the Gulf of Mexico, Southeast Asia, and the Pacific. Unlike phototrophic algae, it thrives in darkness using organic carbon substrates, making it ideal for closed-vessel industrial fermentation. Commercial production has been conducted since the early 1990s in controlled bioreactor environments, with strains optimized for high-density heterotrophic growth using glucose or glycerol as carbon sources under regulated pH, temperature (25–28°C), and dissolved oxygen conditions.
“Schizochytrium sp. has no documented history of traditional medicinal or dietary use in any indigenous or classical medical system; it was unknown as a nutritional resource prior to modern marine biology research. The genus was first characterized scientifically in the mid-20th century as part of thraustochytrid marine protist taxonomy, and its commercial significance emerged in the 1990s when Martek Biosciences (later DSM Nutritional Products) developed it as a scalable heterotrophic fermentation platform for infant formula DHA supplementation. Its adoption was driven by concerns over fish oil sustainability, ocean contaminant accumulation (PCBs, mercury, dioxins), and the growing vegan supplement market rather than any cultural or ethnobotanical tradition. The transition from fish-derived to microalgae-derived omega-3 represents a modern biotechnological innovation in nutritional science, with Schizochytrium sp. oils receiving GRAS status from the FDA and novel food approval from EFSA, cementing their role as a 21st-century functional ingredient.”Traditional Medicine
Scientific Research
Human clinical evidence specific to Schizochytrium sp.-derived EPA/DHA is absent in the published literature reviewed; most available research addresses industrial fermentation optimization, metabolic engineering of PUFA biosynthesis pathways, and animal feed biofortification rather than controlled human trials. The broader algal DHA/EPA literature—supported by multiple randomized controlled trials conducted with algal oil supplements (e.g., life'sDHA, Martek formulations)—demonstrates bioequivalence to fish oil in raising erythrocyte DHA status and comparable triglyceride-lowering effects, providing indirect evidence for Schizochytrium-derived oils. Bovine supplementation research (three-group controlled designs with control, low-dose, and high-dose Schizochytrium cohorts) quantified statistically significant increases in intramuscular EPA (4–6×) and DHA (8.5–11.4×) and reduced n-6:n-3 ratios (p<0.001), confirming biological activity of the oil in vivo, though extrapolation to human supplementation outcomes requires caution. The overall human evidence base for this specific microalgae source remains at preclinical and indirect levels; regulatory bodies (EFSA, FDA GRAS) have approved Schizochytrium sp. DHA oil based on compositional equivalence and safety assessments rather than independent human efficacy trials.
Preparation & Dosage
Traditional preparation
**Oil Capsules (Softgel)**
250–500 mg combined EPA+DHA per capsule, with 1–2 capsules daily recommended for general health maintenance per international guidelines (WHO, EFSA)
Most common commercial form; typical doses provide .
**Liquid Algal Oil**
1–2 mL/day to achieve 200–400 mg DHA
Bulk or bottled oil containing 40–50% DHA by weight of total fatty acids; used in food fortification and direct supplementation at .
**Standardization**
Commercial Schizochytrium sp. oils are standardized to minimum DHA content (commonly ≥35–50% of total fatty acids); EPA content is not typically standardized due to lower concentration (<10% of fatty acids).
**Therapeutic Dose Range**
2–4 g/day combined EPA+DHA (prescription-equivalent dosing); for general anti-inflammatory and cognitive support, 250–1000 mg/day DHA+EPA combined is clinically referenced
For cardiovascular triglyceride reduction, .
**Fermentation-Derived Production**
Schizochytrium sp. is cultured heterotrophically in closed bioreactors on glucose/glycerol media; biomass is harvested, lipids extracted via hexane or supercritical CO2 extraction, and refined to remove volatile contaminants before encapsulation.
**Timing**
Best absorbed when taken with a fat-containing meal, which stimulates bile secretion and enhances micellarization and absorption of PUFA-rich lipid droplets in the small intestine.
**Triglyceride vs. Ethyl Ester Form**
Algal oils from Schizochytrium sp. are naturally in triglyceride form, which demonstrates approximately 70% greater bioavailability compared to ethyl ester pharmaceutical forms under fed conditions.
Nutritional Profile
Schizochytrium sp. biomass contains approximately 40–50% total lipid by dry weight under optimized fermentation conditions, with PUFAs dominating the fatty acid profile. DHA (C22:6 n-3) constitutes 40–50% of total fatty acids; EPA (C20:5 n-3) contributes less than 10%, typically 3–8% depending on strain and culture conditions; docosapentaenoic acid (DPA, C22:5 n-3) is present at 5–15%. Saturated fatty acids including palmitic acid (C16:0) comprise 20–35% of total fatty acids, with engineered KR-overexpressing strains showing reduced palmitate accumulation. Co-occurring bioactives include carotenoids (predominantly astaxanthin precursors and beta-carotene), squalene (a triterpene with antioxidant properties), and exopolysaccharides with reported antiviral activity in preliminary studies. Protein content of defatted biomass ranges from 15–25% dry weight, though the oil extract itself is essentially protein-free. Bioavailability of DHA from Schizochytrium oil is high when delivered in triglyceride form with dietary fat; lipid matrix and emulsification status are the primary determinants of intestinal absorption efficiency.
How It Works
Mechanism of Action
EPA (C20:5 n-3) and DHA (C22:6 n-3) from Schizochytrium sp. are biosynthesized through a polyketide synthase-like (PKS) multi-enzyme complex—rather than the conventional fatty acid synthase (FAS) pathway—using malonyl-CoA extender units with iterative reduction steps catalyzed by ketoacyl-ACP reductase (KR) and dehydratase (DH) domains, enabling anaerobic PUFA chain elongation without molecular oxygen. Upon ingestion, EPA and DHA are incorporated into phospholipid bilayers of cell membranes, displacing arachidonic acid (AA, C20:4 n-6) and altering membrane fluidity, lipid raft organization, and G-protein-coupled receptor (GPCR) signaling dynamics. EPA competitively inhibits cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) from converting AA into pro-inflammatory prostaglandins (PGE2) and leukotrienes (LTB4), while instead serving as substrate for the biosynthesis of E-series resolvins (RvE1, RvE2) that bind ChemR23 and BLT1 receptors to actively promote inflammatory resolution. DHA activates GPR120 (free fatty acid receptor 4) on macrophages and adipocytes, inhibiting IKKβ phosphorylation and subsequent NF-κB nuclear translocation, thereby suppressing transcription of inflammatory cytokine genes including TNF-α, IL-6, and MCP-1.
Clinical Evidence
No published human randomized controlled trials have specifically tested Schizochytrium sp.-derived EPA/DHA supplementation as an intervention with clinical endpoints such as cardiovascular events, inflammatory biomarkers, or cognitive outcomes. Indirect clinical support derives from the established omega-3 literature: meta-analyses of EPA/DHA supplementation (1–4 g/day) demonstrate 15–30% reductions in serum triglycerides, modest reductions in systolic blood pressure (~2–3 mmHg), and significant increases in erythrocyte omega-3 index, with FDA-approved pharmaceutical-grade EPA (icosapentaenoic acid ethyl ester, 4 g/day) reducing cardiovascular events by 25% in the REDUCE-IT trial (n=8,179). Algal DHA oils from related Schizochytrium strains have been shown in smaller human trials to raise plasma DHA levels equivalently to fish oil at matched DHA doses, supporting bioequivalence but not independent superiority. Confidence in applying these broader omega-3 clinical findings to Schizochytrium sp. oil is moderate, contingent on verified EPA+DHA content per dose and triglyceride-form lipid presentation for optimal bioavailability.
Safety & Interactions
Schizochytrium sp.-derived omega-3 oil is classified as GRAS by the FDA and has received novel food approval by EFSA, with no unique toxicological concerns identified beyond those of omega-3 fatty acids generally; at recommended doses of 250–2000 mg/day, side effects are limited to mild gastrointestinal symptoms including fishy aftertaste, nausea, or loose stools, though the algal source produces less oxidative degradation byproducts and no marine contaminants compared to fish oil. At doses exceeding 3 g/day EPA+DHA, clinically relevant antiplatelet effects may potentiate the action of anticoagulants (warfarin, heparin, direct oral anticoagulants) and antiplatelet agents (aspirin, clopidogrel), increasing bleeding risk; prescribers should monitor INR in anticoagulated patients initiating high-dose algal omega-3 supplementation. High-dose omega-3 (4 g/day) may modestly increase LDL-cholesterol in some individuals with hypertriglyceridemia, though DHA-predominant algal oils show less LDL elevation than EPA-only formulations. Schizochytrium sp. oil is considered safe in pregnancy and lactation—DHA is actively recommended (200–300 mg/day) during gestation for fetal neurodevelopment—and the algal source is preferred over fish oil due to absence of methylmercury and PCB contamination risk.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Schizochytrium sp.Algal DHA oilMicroalgae omega-3Thraustochytrid oilVegan omega-3DHA algal oil
Frequently Asked Questions
Is omega-3 from Schizochytrium microalgae as effective as fish oil?
Algal DHA oil from Schizochytrium sp. has been shown in human bioequivalence studies to raise plasma and erythrocyte DHA levels equivalently to fish oil at matched DHA doses, confirming comparable bioavailability when delivered in triglyceride form. The algal source provides DHA and EPA without marine contaminants such as methylmercury or PCBs, and is delivered in the natural triglyceride form, which is absorbed approximately 70% more efficiently than the ethyl ester forms used in some fish oil concentrates.
What is the recommended daily dose of Schizochytrium-derived omega-3 for adults?
For general health maintenance, international guidelines (WHO, EFSA, AHA) recommend 250–500 mg combined EPA+DHA daily, achievable with one to two standard algal omega-3 softgel capsules. For specific therapeutic goals such as triglyceride reduction, clinical evidence supports doses of 2–4 g/day EPA+DHA, though at these higher doses medical supervision is advisable due to antiplatelet and potential LDL-modulating effects.
Can vegans and vegetarians take Schizochytrium omega-3 supplements?
Yes—Schizochytrium sp. is a microalgae (a marine protist) cultivated via heterotrophic fermentation on plant-derived carbon sources such as glucose or glycerol, making the resulting DHA/EPA oil entirely free of animal-derived ingredients and suitable for vegan and vegetarian diets. This source bypasses the need to consume fish, whose omega-3 content itself originates from microalgae consumed lower in the marine food chain.
Does algal omega-3 from Schizochytrium contain significant amounts of EPA?
Schizochytrium sp. naturally produces DHA as its dominant n-3 PUFA, comprising 40–50% of total fatty acids, while EPA content is typically low at 3–8% of total fatty acids depending on strain genetics and fermentation conditions. Consumers seeking high EPA concentrations for specific applications (such as mood support or inflammation reduction dominated by EPA's resolvin E-series) may need to seek EPA-enriched algal strains or combine Schizochytrium DHA oil with separate EPA sources.
Are there any drug interactions or safety concerns with Schizochytrium omega-3 supplements?
At doses above 3 g/day EPA+DHA, Schizochytrium-derived omega-3 oil can potentiate the anticoagulant effects of warfarin, heparin, and direct oral anticoagulants (apixaban, rivaroxaban), as well as antiplatelet drugs like aspirin and clopidogrel, increasing bleeding risk; INR monitoring is recommended for anticoagulated patients. At standard supplemental doses (250–1000 mg/day), the safety profile is excellent—the algal source avoids fish allergy concerns and ocean-derived contaminants, and FDA GRAS and EFSA novel food status confirm an established safety record.
What is the bioavailability difference between Schizochytrium algal omega-3 and plant-based ALA sources?
Schizochytrium microalgae provides pre-formed EPA and DHA in their active forms, bypassing the inefficient conversion process required from plant-based alpha-linolenic acid (ALA), where only 5–10% converts to EPA in the human body. This direct bioavailability makes algal omega-3 significantly more efficient at raising circulating EPA and DHA levels compared to flax or chia seed sources. Algal-derived EPA and DHA achieve comparable blood concentration increases to fish oil within the same dose range.
How does Schizochytrium omega-3 support heart health compared to reducing cholesterol alone?
Schizochytrium-derived EPA and DHA lower cardiovascular risk through multiple mechanisms beyond cholesterol reduction, including reducing serum triglycerides by 20–30%, decreasing platelet aggregation to reduce clot risk, and improving endothelial function through nitric oxide upregulation. These complementary pathways address inflammation and vascular function—independent of LDL cholesterol levels—making algal omega-3 particularly valuable for individuals with elevated triglycerides or endothelial dysfunction. This multi-target mechanism explains why omega-3 supplementation provides cardiovascular benefit even when cholesterol levels are already controlled.
Is Schizochytrium microalgae omega-3 appropriate for people with shellfish or fish allergies?
Yes, Schizochytrium-derived omega-3 is safe for individuals with shellfish or fish allergies because it is cultivated from a single-celled microalga grown in controlled fermentation systems, containing no fish proteins or shellfish allergens. Unlike fish oil supplements that may carry cross-contamination risks, algal omega-3 production avoids the marine environment entirely, making it an ideal hypoallergenic alternative. Individuals with documented shellfish allergies should still verify product labeling for allergen statements and consult their healthcare provider if severe allergies are present.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w omega-3-epadha-schizochytrium-sp-microalgae curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
